Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $24.9 million.

  • Editas Medicine's Non-Current Assets fell 5594.39% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.7 million, marking a year-over-year decrease of 6791.72%. This contributed to the annual value of $52.3 million for FY2024, which is 6698.29% down from last year.
  • As of Q3 2025, Editas Medicine's Non-Current Assets stood at $24.9 million, which was down 5594.39% from $27.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Non-Current Assets ranged from a high of $170.2 million in Q4 2021 and a low of $24.9 million during Q3 2025
  • For the 5-year period, Editas Medicine's Non-Current Assets averaged around $110.2 million, with its median value being $126.1 million (2022).
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 25545.15% in 2021, then tumbled by 7177.67% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Non-Current Assets stood at $170.2 million in 2021, then decreased by 7.41% to $157.6 million in 2022, then grew by 0.48% to $158.3 million in 2023, then plummeted by 66.98% to $52.3 million in 2024, then plummeted by 52.44% to $24.9 million in 2025.
  • Its Non-Current Assets stands at $24.9 million for Q3 2025, versus $27.8 million for Q2 2025 and $38.8 million for Q1 2025.